These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9882342)

  • 1. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
    Skiadopoulos MH; Surman S; Tatem JM; Paschalis M; Wu SL; Udem SA; Durbin AP; Collins PL; Murphy BR
    J Virol; 1999 Feb; 73(2):1374-81. PubMed ID: 9882342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
    Skiadopoulos MH; Durbin AP; Tatem JM; Wu SL; Paschalis M; Tao T; Collins PL; Murphy BR
    J Virol; 1998 Mar; 72(3):1762-8. PubMed ID: 9499025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
    Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
    Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3).
    Stokes A; Tierney EL; Sarris CM; Murphy BR; Hall SL
    Virus Res; 1993 Oct; 30(1):43-52. PubMed ID: 8266719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys.
    Hall SL; Stokes A; Tierney EL; London WT; Belshe RB; Newman FC; Murphy BR
    Virus Res; 1992 Mar; 22(3):173-84. PubMed ID: 1320790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
    Skiadopoulos MH; Tao T; Surman SR; Collins PL; Murphy BR
    Vaccine; 1999 Oct; 18(5-6):503-10. PubMed ID: 10519940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.
    Hall SL; Sarris CM; Tierney EL; London WT; Murphy BR
    J Infect Dis; 1993 Apr; 167(4):958-62. PubMed ID: 8383726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
    Skiadopoulos MH; Surman SR; Durbin AP; Collins PL; Murphy BR
    Virology; 2000 Jun; 272(1):225-34. PubMed ID: 10873765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.
    Whitehead SS; Firestone CY; Collins PL; Murphy BR
    Virology; 1998 Aug; 247(2):232-9. PubMed ID: 9705916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.
    Clements ML; Belshe RB; King J; Newman F; Westblom TU; Tierney EL; London WT; Murphy BR
    J Clin Microbiol; 1991 Jun; 29(6):1175-82. PubMed ID: 1650789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
    Whitehead SS; Firestone CY; Karron RA; Crowe JE; Elkins WR; Collins PL; Murphy BR
    J Virol; 1999 Feb; 73(2):871-7. PubMed ID: 9882287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
    Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine.
    Subbarao EK; Park EJ; Lawson CM; Chen AY; Murphy BR
    J Virol; 1995 Oct; 69(10):5969-77. PubMed ID: 7666501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
    Durbin AP; Skiadopoulos MH; McAuliffe JM; Riggs JM; Surman SR; Collins PL; Murphy BR
    J Virol; 2000 Aug; 74(15):6821-31. PubMed ID: 10888621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations.
    Juhasz K; Whitehead SS; Boulanger CA; Firestone CY; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(11-12):1416-24. PubMed ID: 10195777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
    McAuliffe JM; Surman SR; Newman JT; Riggs JM; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2029-36. PubMed ID: 14747567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3.
    Crookshanks-Newman FK; Belshe RB
    J Med Virol; 1986 Feb; 18(2):131-7. PubMed ID: 3005486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.